Keyword: Seres Therapeutics
The Parker Institute for Cancer Immunotherapy is sponsoring the trial, which will take place at the MD Anderson Cancer Center.
The combined company starts life with Crestovo’s phase 2 Clostridium difficile candidate and a large-scale stool donation program.
Microbiome startup AOBiome Therapeutics has seen positive data from its phase 2b trial in acne.
The microbiome pioneer thinks the data support the rapid advance of SER-287 deeper into the clinic, although question marks about the results remain.
Nestlé Health Science and Enterome have joined forces to create a microbiome-based diagnostics startup.
Takeda has unveiled its second microbiome pact in a week to continue its gastrointestinal deal spree.
Seres Therapeutics has unveiled the design of a phase 2 trial it thinks could secure FDA approval for its microbiome drug.
Seres Therapeutics has plotted a path forward for its Clostridium difficile program after digging into the data to learn where it went wrong in phase 2.
An FDA “Breakthrough” tag, which has been around since 2012, was once a highly coveted badge that in essence allows the regulator to help speed up development of new meds, and it was believed initially that these would be fairly rare occurrences held back for some truly innovative treatments.
Seres' oral microbiome therapeutic SER-109 failed to outperform a placebo in Clostridium difficile infection patients in a Phase II trial, sinking its stock.